{"url_path":"/sec/pstv/8-k/2026-06-05/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-05","source_url":"https://www.sec.gov/Archives/edgar/data/1095981/0001193125-26-259703-index.html","accession_number":"0001193125-26-259703","cik":"0001095981","ticker":"PSTV","issuer_name":"PLUS THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1095981/0001193125-26-259703-index.html","primary_entity_key":"0001095981","primary_entity_name":"PLUS THERAPEUTICS, INC."},"word_count":111,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits.\n\n \n\n \n\n \n\nExhibit\n\nNumber\n\nDescription\n\n \n\n \n\n1.1\n\n[Distribution Agreement, dated as of June 1, 2026, by and between Plus Therapeutics, Inc. and Canaccord Genuity LLC (incorporated by reference to Exhibit 1.1 to the Company’s Registration Statement on Form S-3 filed with the SEC on June 2, 2026).](https://www.sec.gov/Archives/edgar/data/1095981/000119312526252119/d138711dex11.htm)\n\n \n\n \n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n \n\n \n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nPLUS THERAPEUTICS, INC.\n\n \n\n \n\n \n\n \n\nDate:\n\nJune 5, 2026\n\nBy:\n\n/s/ Andrew Sims\n\n \n\n \n\n \n\nAndrew Sims\nChief Financial Officer"}